Jha Praveen, Himanshu D, Jain Nirdesh, Singh Ajay Kumar
Department of Internal Medicine, KGMU., Gwalior, Madhya Pradesh, India.
BMJ Case Rep. 2013 Jan 23;2013:bcr2012007926. doi: 10.1136/bcr-2012-007926.
Imatinib mesylate is a tyrosine kinase inhibitor used widely as the first-line treatment for chronic myeloid leukaemia (CML). The side-effect profile of this drug includes fluid retention, muscle cramps, diarrhoea, myelosuppression and skin rashes. Of these, rashes of the type maculo-papular eruptions and oedema developed most commonly. The cutaneous adverse reactions other than maculo-papular eruptions are rare with imatinib. Severe and life-threatening cutaneous reactions can occur in 5% cases. Here, the author reports a case of newly diagnosed CML that developed Steven-Johnsons syndrome due to imatinib therapy. Patient responded and discharged successfully on withdrawal of the culminating drug.
甲磺酸伊马替尼是一种酪氨酸激酶抑制剂，被广泛用作慢性粒细胞白血病（CML）的一线治疗药物。该药物的副作用包括液体潴留、肌肉痉挛、腹泻、骨髓抑制和皮疹。其中，最常见的是斑丘疹和水肿型皮疹。伊马替尼引起的除斑丘疹以外的皮肤不良反应很少见。5%的病例可能会发生严重的、危及生命的皮肤反应。在此，作者报告一例新诊断的CML患者，因伊马替尼治疗发生了史蒂文斯-约翰逊综合征。患者在停用最终导致不良反应的药物后病情好转并成功出院。
